Subscribe50$/product give away!

Submit an Article to Pharmacy HQ     
Please include the author's name, title, and citations.     

APRISO- mesalamine capsule, extended release

  1. Patient Information
  2. Manufactured For:

Patient Information 

Patients with Phenylketonuria

Inform patients with phenylketonuria (PKU) or their caregivers that each APRISO capsule contains aspartame equivalent to 0.56 mg of phenylalanine, so that the recommended adult dosing provides an equivalent of 2.24 mg of phenylalanine per day.

General Counseling Information

Instruct patients not to take APRISO capsules with antacids, because it could affect the way APRISO dissolves.
Instruct patients to contact a health care provider if they experience a worsening of ulcerative colitis symptoms, because it could be due to a reaction to APRISO.

Manufactured For: 

Salix Pharmaceuticals, a division of Valeant Pharmaceuticals North America LLC
Bridgewater, NJ 08807 USA

U.S. Patent Numbers: 6,551,620; 7,547,451; 8,337,886; 8,496,965; 8,865,688; 8,911,778; 8,940,328; and 8,956,647

Apriso is a trademark of Valeant Pharmaceuticals International, Inc., or its affiliates.

Valeant Pharmaceuticals North America LLC

Please see www.salix.com for patent information.


Your use of this website constitutes your agreement to the terms and conditions linked below:
Terms and Conditions | Resources
2017 © Copyright PharmacyHQ.com. Questions?
Please contact: pharmacyhq.mail@gmail.com